4.5 Article

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 75, Issue 4, Pages 979-989

Publisher

WILEY
DOI: 10.1111/j.1365-2125.2012.04416.x

Keywords

cardiac repolarization; exenatide; thorough QT; QTc study

Funding

  1. Amylin Pharmaceuticals, Inc.
  2. Eli Lilly and Co.

Ask authors/readers for more resources

Aims Exenatide has been demonstrated to improve glycaemic control in patients with type 2 diabetes, with no effect on heart rate corrected QT (QTc) at therapeutic concentrations. This randomized, placebo- and positive-controlled, crossover, thorough QT study evaluated the effects of therapeutic and supratherapeutic exenatide concentrations on QTc. Methods Intravenous infusion was employed to achieve steady-state supratherapeutic concentrations in healthy subjects within a reasonable duration (i.e. days). Subjects received exenatide, placebo and moxifloxacin, with ECGs recorded pre-therapy and during treatment. Intravenous exenatide was expected to increase heart rate to a greater extent than subcutaneous twice daily or once weekly formulations. To assure proper heart rate correction, a wide range of baseline heart rates was assessed and prospectively defined methodology was applied to determine the optimal QT correction. Results Targeted steady-state plasma exenatide concentrations were exceeded (geometric mean +/- SEM 253 +/- 8.5pgml1, 399 +/- 11.9pgml1 and 627 +/- 21.2pgml1). QTcP, a population-based method, was identified as the most appropriate heart rate correction and was prespecified for primary analysis. The upper bound of the two-sided 90% confidence interval for placebo-corrected, baseline-adjusted QTcP (QTcP) was <10ms at all time points and exenatide concentrations. The mean of three measures assessed at the highest steady-state plasma exenatide concentration of approximate to 500pgml1 (QTcPavg) was 1.13 [2.11, 0.15). No correlation was observed between QTcP and exenatide concentration. Assay sensitivity was confirmed with moxifloxacin. Conclusions These results demonstrated that exenatide, at supratherapeutic concentrations, does not prolong QTc and provide an example of methodology for QT assessment of drugs with an inherent heart rate effect.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available